Canaccord Genuity restated their buy rating on shares of KemPharm, Inc. (NASDAQ:KMPH) in a report published on Monday morning. The brokerage currently has a $7.00 price target on the specialty pharmaceutical company’s stock.
KMPH has been the subject of a number of other research reports. Roth Capital started coverage on shares of KemPharm in a research note on Wednesday, June 28th. They issued a buy rating and a $8.00 price objective for the company. Zacks Investment Research lowered shares of KemPharm from a hold rating to a sell rating in a research note on Tuesday, May 16th. Oppenheimer Holdings, Inc. set a $13.00 price objective on shares of KemPharm and gave the stock a buy rating in a research note on Thursday, August 10th. ValuEngine raised shares of KemPharm from a strong sell rating to a sell rating in a research note on Saturday, July 1st. Finally, Royal Bank Of Canada reaffirmed a buy rating and issued a $8.00 price objective on shares of KemPharm in a research note on Monday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. KemPharm presently has a consensus rating of Buy and an average target price of $8.10.
KemPharm (NASDAQ:KMPH) opened at 3.39 on Monday. The stock’s market cap is $49.69 million. KemPharm has a 52 week low of $2.45 and a 52 week high of $5.40. The firm’s 50 day moving average price is $3.06 and its 200-day moving average price is $3.80.
KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.19. Analysts expect that KemPharm will post ($2.72) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “KemPharm, Inc. (KMPH) Rating Reiterated by Canaccord Genuity” was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/15/kempharm-inc-kmph-rating-reiterated-by-canaccord-genuity.html.
In related news, CEO Travis C. Mickle bought 8,000 shares of the firm’s stock in a transaction on Tuesday, June 20th. The stock was bought at an average price of $3.45 per share, with a total value of $27,600.00. Following the purchase, the chief executive officer now directly owns 1,629,612 shares of the company’s stock, valued at approximately $5,622,161.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have acquired a total of 17,275 shares of company stock valued at $51,808 in the last three months. Company insiders own 22.80% of the company’s stock.
Several large investors have recently modified their holdings of KMPH. Bank of New York Mellon Corp boosted its stake in shares of KemPharm by 17.6% during the 1st quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of KemPharm during the 1st quarter valued at $647,000. Finally, C WorldWide Group Holding A S boosted its stake in shares of KemPharm by 110.1% during the 2nd quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after buying an additional 200,000 shares during the period. 40.01% of the stock is owned by institutional investors.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.